222 related articles for article (PubMed ID: 25071181)
1. EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells.
De S; Dermawan JK; Stark GR
Proc Natl Acad Sci U S A; 2014 Aug; 111(32):11721-6. PubMed ID: 25071181
[TBL] [Abstract][Full Text] [Related]
2. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Burga LN; Hu H; Juvekar A; Tung NM; Troyan SL; Hofstatter EW; Wulf GM
Breast Cancer Res; 2011 Mar; 13(2):R30. PubMed ID: 21396117
[TBL] [Abstract][Full Text] [Related]
3. The Sos1 and Sos2 Ras-specific exchange factors: differences in placental expression and signaling properties.
Qian X; Esteban L; Vass WC; Upadhyaya C; Papageorge AG; Yienger K; Ward JM; Lowy DR; Santos E
EMBO J; 2000 Feb; 19(4):642-54. PubMed ID: 10675333
[TBL] [Abstract][Full Text] [Related]
4. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
Bivona TG; Hieronymus H; Parker J; Chang K; Taron M; Rosell R; Moonsamy P; Dahlman K; Miller VA; Costa C; Hannon G; Sawyers CL
Nature; 2011 Mar; 471(7339):523-6. PubMed ID: 21430781
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.
De S; Zhou H; DeSantis D; Croniger CM; Li X; Stark GR
Proc Natl Acad Sci U S A; 2015 Aug; 112(31):9680-5. PubMed ID: 26195767
[TBL] [Abstract][Full Text] [Related]
6. EGFR and NF-κB: partners in cancer.
Shostak K; Chariot A
Trends Mol Med; 2015 Jun; 21(6):385-93. PubMed ID: 25979753
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
[TBL] [Abstract][Full Text] [Related]
8. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.
Cao C; Lu S; Sowa A; Kivlin R; Amaral A; Chu W; Yang H; Di W; Wan Y
Cancer Lett; 2008 Aug; 266(2):249-62. PubMed ID: 18400375
[TBL] [Abstract][Full Text] [Related]
9. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
Frolov A; Schuller K; Tzeng CW; Cannon EE; Ku BC; Howard JH; Vickers SM; Heslin MJ; Buchsbaum DJ; Arnoletti JP
Cancer Biol Ther; 2007 Apr; 6(4):548-54. PubMed ID: 17457047
[TBL] [Abstract][Full Text] [Related]
10. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
[TBL] [Abstract][Full Text] [Related]
11. FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaB.
Guo C; Stark GR
Proc Natl Acad Sci U S A; 2011 May; 108(19):7968-73. PubMed ID: 21518868
[TBL] [Abstract][Full Text] [Related]
12. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
13. Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells.
Lin Y; Higashisaka K; Shintani T; Maki A; Hanamuro S; Haga Y; Maeda S; Tsujino H; Nagano K; Fujio Y; Tsutsumi Y
Sci Rep; 2020 Mar; 10(1):4748. PubMed ID: 32179851
[TBL] [Abstract][Full Text] [Related]
14. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
15. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.
Fujioka N; Nguyen J; Chen C; Li Y; Pasrija T; Niehans G; Johnson KN; Gupta V; Kratzke RA; Gupta K
Anesth Analg; 2011 Dec; 113(6):1353-64. PubMed ID: 22003224
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells.
Biswas DK; Cruz AP; Gansberger E; Pardee AB
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8542-7. PubMed ID: 10900013
[TBL] [Abstract][Full Text] [Related]
17. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
[TBL] [Abstract][Full Text] [Related]
18. Arsenic activates EGFR pathway signaling in the lung.
Andrew AS; Mason RA; Memoli V; Duell EJ
Toxicol Sci; 2009 Jun; 109(2):350-7. PubMed ID: 19168569
[TBL] [Abstract][Full Text] [Related]
19. Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells.
Huang DH; Su L; Peng XH; Zhang H; Khuri FR; Shin DM; Chen ZG
Nanotechnology; 2009 Jun; 20(22):225102. PubMed ID: 19433879
[TBL] [Abstract][Full Text] [Related]
20. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Younes M; Wu Z; Dupouy S; Lupo AM; Mourra N; Takahashi T; Fléjou JF; Trédaniel J; Régnard JF; Damotte D; Alifano M; Forgez P
Oncotarget; 2014 Sep; 5(18):8252-69. PubMed ID: 25249545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
